Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden

Autor: David Robinson, Eugenio Ventimiglia, Pär Stattin, Magnus Törnblom, Ingela Franck Lissbrant, Mats Lambe, Marie Hjälm-Eriksson, Y. Folkvaljon
Rok vydání: 2018
Předmět:
Male
Time Factors
030232 urology & nephrology
Disease
Logistic regression
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
Residence Characteristics
Urologi och njurmedicin
Medicine
Registries
castrationresistant prostate cancer
Neoplasm Metastasis
Abiraterone
Aged
80 and over
education.field_of_study
enzalutamide
Age Factors
Middle Aged
Prostatic Neoplasms
Castration-Resistant
Nephrology
030220 oncology & carcinogenesis
Benzamides
Marital status
Educational Status
Androstenes
medicine.medical_specialty
Urology
Population
Antineoplastic Agents
Drug Prescriptions
03 medical and health sciences
Internal medicine
Nitriles
Phenylthiohydantoin
Urology and Nephrology
Enzalutamide
Humans
Medical prescription
education
Aged
Sweden
business.industry
Prostatic Neoplasms
Androgen Antagonists
medicine.disease
Comorbidity
Cross-Sectional Studies
chemistry
business
Zdroj: Scandinavian journal of urology. 52(2)
ISSN: 2168-1813
Popis: Objectives: The aim of this study was to examine the use of abiraterone and enzalutamide, two oral novel antiandrogens (NOVAs), in men with prostate cancer (PCa) in Sweden. Materials and methods: This cross-sectional study investigated filled prescriptions for NOVAs recorded in the Swedish Prescribed Drug Register between July 2015 and April 2016. Associations between age, comorbidity, educational level, marital status and county of residence and filled prescriptions were analyzed in the National Prostate Cancer Register (NPCR) and other health population-based registers, using multivariable logistic regression. Results: Of 91,209 men, 1650 (2%) had at least one prescription filled for NOVAs, of whom 1350 (82%) had high-risk or metastatic PCa at diagnosis.. Of 1914 men with M1 disease and a high probability of castration-resistant prostate cancer (CRPC), 22% had a prescription for NOVAs at a median 3 years after the date of diagnosis. At multivariable logistic regression analysis,, the likelihood of NOVA use was lower in older men [age >80 vs Conclusions: Less than one-third of potentially eligible men with CRPC received NOVAs in 2015–2016. There were large differences in use according to age and region of residence, indicating that efforts are needed to improve equal access to novel cancer drugs.
Databáze: OpenAIRE
Externí odkaz: